Markets:

Overview

News

Currencies

International

Treasuries

Defence Therapeutics Inc (CSE:DTC)

0.7100 +0.0100 (+1.43%)

Streaming Delayed Price Updated: 11:49 AM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Defence Therapeutics Inc

Life Sciences Virtual Investor Forum Agenda Announced for December 11th

December 09, 2025

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Precision Medicine Helps Conquer Advanced-Stage Cancer

November 14, 2023

As North America reports a dramatic rise in advanced-stage cancer cases, experts are saying that major breakthroughs in oncology could make “now the best time in human history to get cancer.” According...

Via PressReach

Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors

November 14, 2023

(November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in

Via PressReach

Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

November 14, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END

Via FinancialNewsMedia

Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology

November 07, 2023

(November 7, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing cutting-edge

Via PressReach

Topics Intellectual Property

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

Via FinancialNewsMedia

Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer

October 18, 2023

(October 18, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the

Via PressReach

Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race

October 17, 2023

Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to...

Via PressReach

Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology

October 17, 2023

Leading pharmaceutical companies are diving headfirst into oncology, sparking a buzz in the cancer treatment world. Bristol Myers Squibb is the latest company to join the movement, announcing its plan...

Via PressReach

Defence’s Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma

October 17, 2023

(October 17, 2023) - Defence Therapeutics Inc. (CSE:DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology

Via PressReach

Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race

October 10, 2023

Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...

Via PressReach

Big Pharma’s Billion-Dollar Bets on Advanced Cancer Therapies

October 10, 2023

Big Pharma is continuing its oncology buying spree, with a flurry of multi-billion-dollar deals, partnerships, and investments creating a buzz in the cancer treatment space. American pharmaceutical...

Via PressReach

Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science

October 10, 2023

(October 10, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a biotechnology company developing various products for the

Via PressReach

Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines

September 26, 2023

(September 25, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the

Via PressReach

BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment

May 10, 2023

Vancouver, British Columbia--(Newsfile Corp. - May 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) - Defence Therapeutics...

Via Newsfile

BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News

May 04, 2023

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2023) - On FOX Business News broadcast on Sunday, May 7 at 5:30...

Via Newsfile

Topics Supply Chain

BTV Features: Defence Therapeutics, Volatus Aerospace, NGEx Minerals, York Harbour Metals, & AuTECO Minerals

November 10, 2022

Vancouver, British Columbia--(Newsfile Corp. - November 10, 2022) - On national TV Sat. November 12 & Sun. November 13, 2022...

Via Newsfile

Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market

September 29, 2022

Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"...

Via Newsfile

Topics Death Intellectual Property

Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma

September 21, 2022

Vancouver, British Columbia--(Newsfile Corp. - September 21, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"...

Via Newsfile

Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative

September 16, 2022

Vancouver, British Columbia--(Newsfile Corp. - September 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"...

Via Newsfile

The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants

July 06, 2021

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a biotechnology...

Via Newsfile

Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer

June 29, 2021

Vancouver, British Columbia--(Newsfile Corp. - June 29, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased...

Via Newsfile

Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties

June 22, 2021

Vancouver, British Columbia--(Newsfile Corp. - June 22, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased...

Via Newsfile

Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic

June 07, 2021

Vancouver, British Columbia--(Newsfile Corp. - June 7, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company") is pleased...

Via Newsfile

RETRANSMISSION: Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program

June 01, 2021

Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a pre-clinical...

Via Newsfile

Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program

May 31, 2021

Vancouver, British Columbia--(Newsfile Corp. - May 31, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a pre-clinical...

Via Newsfile

Defence Therapeutics AccuVAC-D001 Cancer Vaccine Generates Effective Long-lasting Anti-Tumoral Response

May 25, 2021

Vancouver, British Columbia--(Newsfile Corp. - May 25, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased...

Via Newsfile

Defence Therapeutics, Strong Therapeutics Pipeline: ADC's, Cancer and COVID Vaccines

May 07, 2021

Vancouver, British Columbia--(Newsfile Corp. - May 7, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian...

Via Newsfile

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.